

Source

Monoclonal Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.

Clone

101F

Species

Mouse

Isotype

Mouse IgG2a | Mouse Kappa

Conjugate

Unconjugated

Antibody Type

Recombinant Monoclonal

Reactivity

Virus

Specificity

This product is a specific antibody specifically reacts with RSV-F0.

Application

ELISA

Application	Recommended Usage

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A purified/ Protein G purified

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20 $^{\circ}$ C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



0.2-78 ng/mL

Monoclonal Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Discounts, Gifts, and more!


Acro

Monoclonal Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F)


Catalog # RSF-M309a



Bioactivity-ELISA



Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) at 2 μ g/mL (100 μ L/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) (Cat. No. AM309a) with a linear range of 0.2-10 ng/mL (QC tested).



Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 2 μ g/mL (100 μ L/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) (Cat. No. AM309a) with a linear range of 0.2-10 ng/mL (QC tested).

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Antibody 101F, target epitopes that have been mapped to linear regions in the F1 subunit, referred to as antigenic site IV.

Clinical and Translational Updates

